Wegener Granulomatosis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2026-08-21
EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France
The EMA revoked Tavneos (avacopan) for its indications, including Microscopic Polyangiitis and Wegener Granulomatosis, effective January 15,…
EMA withdrawal · 2026-08-19
EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France
The EMA revoked Tavneos (avacopan) authorization for indications including Microscopic Polyangiitis and Wegener Granulomatosis.
CLINICAL_TRIALS trial_result · 2022-03-18
Clinical Trial Update: Rituximab Vasculitis Maintenance Study [Phase 3]
Phase 3 clinical trial update for rituximab maintenance in ANCA-associated vasculitis, including microscopic polyangiitis and Wegener granul…
EMA withdrawal · 2021-08-16
EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic …
CLINICAL_TRIALS trial_result · 2021-07-20
Clinical Trial Update: Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases [Phase 2]
Phase 2 clinical trial evaluating low-dose IL-2 to induce regulatory T cells in various autoimmune and inflammatory diseases; trial complete…
Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
CLINICAL_TRIALS trial_result · 2021-01-27
Clinical Trial Update: Low-dose Glucocorticoid Vasculitis Induction Study [Phase 4]
Phase 4 clinical trial update investigating low-dose glucocorticoids for induction in vasculitis conditions.
EMA withdrawal · 2019-07-08
EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
EMA withdrawal · 2008-06-19
EMA Application withdrawn: Spanidin (gusperimus trihydrochloride) — Euro Nippon Kayaku GmbH
EU application for Spanidin (gusperimus trihydrochloride) withdrawn; previously targeted Wegener Granulomatosis (granulomatosis with polyang…